* Apyx Medical Corp APYX.OQ APYX.O is expected to show a
rise
in quarterly revenue when it reports results on August 10.
* The Clearwater Florida-based company is expected to
report a
39.2% increase in revenue to $14.325 million from $10.29 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Apyx Medical Corp
is for
a loss of 7 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Apyx
Medical Corp
is $9, above its last closing price of $4.45.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.16 -0.13 -0.10 Beat 25.9
Dec. 31 2023 -0.15 -0.14 -0.17 Missed -19.3
Sep. 30 2022 -0.15 -0.14 -0.17 Missed -17.2
Jun. 30 2022 -0.19 -0.19 -0.16 Beat 14.7
Mar. -0.14 -0.15 -0.17 Missed -15.9
31 2022
Dec. 31 2021 -0.10 -0.11 -0.06 Beat 45.5
Sep. 30 2021 -0.15 -0.15 -0.12 Beat 20
Jun. 30 2021 -0.16 -0.15 -0.12 Beat 18.5
This summary was machine generated August 9 at 02:03 GMT. All
figures in US dollars unless otherwise stated